Priority review voucher updates: Who's won PRVs, who's bought them, and how much they're selling for
Tracker updated on 5/30/24 to note that Day One sold for $108 million its rare pediatric PRV for the approval of Ojemda (tovorafenib) for children …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.